Altimmune (NASDAQ:ALT) inks an agreement with
DynPort Vaccine Company to coordinate U.S. government funding efforts
for AdCOVID, its single-dose intranasal COVID-19 vaccine candidate.
If successful with the funding, DynPort will
provide program management, drug development activity integration and
regulatory support services for AdCOVID.
Altimmune expects to launch manufacturing this quarter followed by a Phase 1 clinical trial in Q4.
The company has secured government funding for two
other programs: NasoShield, a single-dose intranasal anthrax vaccine
candidate, and T-COVID, an intranasal therapeutic for early COVID-19.
Both are based on the same replication-deficient adenovirus 5 platform
as AdCOVID.